Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Clonazepam(click to collapse)
1/4 selected
Clonazepam
Klonopin
Benzodiazepine · C-IV
FDA-approved indications
- Panic disorder, with or without agoraphobia, as defined in DSM-V
Off-label uses
- Social anxiety disorder
- REM sleep behavior disorder
- Restless legs syndrome
MechanismBenzodiazepine [EPC]
Half-life30 to 40 hours
Decision GuideWhen to pick each / when to consider an alternative
Clonazepam
Consider when
- Panic disorder — FDA-approved; long t½ (~30–40 h) provides stable levels without interdose anxiety rebound
- Seizure disorder with comorbid anxiety — FDA-approved for absence seizures (Lennox-Gastaut), myoclonic, akinetic seizures
- Once- or twice-daily dosing preferred — long half-life allows BID dosing; better adherence than alprazolam TID-QID
- REM sleep behavior disorder (off-label) — first-line treatment for RBD; unique niche among benzodiazepines
- +1 more
Consider an alternative when
- Substance use disorder history — benzodiazepine class abuse risk; clonazepam has intermediate abuse potential
- Elderly or fall-risk patient — long half-life causes accumulation; Beers Criteria avoid; next-day sedation and falls
- Cognitive preservation important — benzodiazepine class impairs memory and attention; chronic use linked to cognitive decline
- Daytime sedation is problematic — long t½ means sedation carries over; drowsiness is most common side effect
- +1 more
| Axis | Clonazepam benzo |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
Abuse / addiction liability | |
Respiratory depression (opioid / CNS depressant co-use) | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Cognitive dulling / anterograde amnesia | |
| GI | |
Nausea / GI (general) | |
| Discontinuation | |
Withdrawal / discontinuation | |
| Interactions | |
CYP interactions / DDI profile | |
| Safety | |
Overdose toxicity | |
Falls / elderly risk | |
| Pregnancy | |
Lactation / breastfeeding safety | |